SSX2 anticorps (Middle Region)

N° du produit ABIN2784593

Détail du produit anti-SSX2 anticorps

Antigène: SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Épitope: Middle Region

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp SSX2 est non-conjugé

Application: Western Blotting (WB)

Séquence: TFGRLQGISP KIMPKKPAEE G
NDSEEVPEAS GPQNDGKELC PPGKPTTS

Homologie: Human: 100%

Attributs du produit: This is a rabbit polyclonal antibody against SSX2. It was validated on Western Blot.

Purification: Affinity Purified

Immunogène: The immunogen is a synthetic peptide directed towards the middle region of Human SSX2

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: Liquid. Purified antibody supplied in 1x PBS buffer with 0.09 % (w/v) sodium azide and 2 % sucrose.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeat freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: For short term use, store at 2-8°C up to 1 week. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles.

Détails sur SSX2

Antigène: SSX2 (Synovial Sarcoma, X Breakpoint 2 (SSX2))

Autre désignation: SSX2 (SSX2 Produits)

Synonymes: anticorps CT5.2, anticorps CT5.2A, anticorps HD21, anticorps HOM-MEL-40, anticorps SSX, anticorps SSX2, anticorps SSX3, anticorps SSX family member 2, anticorps protein SSX2, anticorps synovial sarcoma, X breakpoint 2, anticorps SSX2, anticorps LOC741661, anticorps Ssx2

Sujet: SSX2 belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneously humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. SSX1, SSX2 and SSX4 genes have been involved in the t(X,18) translocation characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are probably responsible for transforming activity. Two transcript variants encoding distinct isoforms have been identified for this gene.
Alias Symbols: CT5.2a, HD21, HOM-MEL-40, SSX
Protein Interaction Partner: KRT40, SSX2IP, RAB3IP, SYCE1, ZMIZ2, MAGEC2, AKAP9, ZBED1, TAX1BP1, BLZF1, SUZ12, EED, SMARCA5, TLE1, SMARCA2, HDAC2, HDAC1, EZH2, ATF2, RNF2,
Protein Size: 223

Poids moléculaire: 24 kDa

ID gène: 6757

NCBI Accession: NM_175698, NP_783629